Justification for the inclusion of Gag in HIV vaccine candidates

Expert Review of Vaccines

Volumn 15, Issue 5, 2016, Pages 585-598

  Williamson, Anna Lise ^a,b   Rybicki, Edward P ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

BCG; DNA; elite control; HIV; Pr55Gag; SIV; T cell; vaccine; VLP

Indexed keywords

ANTIGEN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS LIKE PARTICLE VACCINE;

CD8+ T LYMPHOCYTE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIREMIA; VIRUS LIKE AGENT; ANIMAL; BLOOD; DISEASE MODEL; HIV INFECTIONS; IMMUNOLOGY; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; T-LYMPHOCYTES; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84951870546     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1129904     Document Type: Review

References (127)

1. Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384 (9947): 1005-1070.
2. Krakower DS, Mayer KH. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Drugs. 2015; 75 (3): 243-251.
3. Sgaier SK, Reed JB, Thomas A, et al. Achieving the HIV prevention impact of voluntary medical male circumcision: lessons and challenges for managing programs. PLoS Med. 2014; 11 (5): e1001641.
4. Plotkin SA. Increasing Complexity of Vaccine Development. J Infect Dis. 2015; 212 (Suppl 1): S12-16.
5. Fauci AS, Folkers GK, Marston HD. Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine. Clin Infect Dis. 2014; 59 (Suppl 2): S80S84.
6. McMichael AJ, Koff WC. Vaccines that stimulate T cell immunity to HIV-1: the next step. Nat Immunol. 2014; 15 (4): 319-322.
7. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47 (3): 401-409.
8. Doria-Rose NA, Schramm CA, Gorman J, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014; 509 (7498): 55-62.
9. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015; 16 (6): 571-576.
10. Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med. 2015; 66: 423-437.
11. Trivedi S, Ranasinghe C. The Influence of Immunization Route, Tissue Microenvironment, and Cytokine Cell Milieu on HIV-Specific CD8+ T Cells Measured Using Fluidigm Dynamic Arrays. Plos One. 2015; 10 (5): e0126487.
12. Smith NM, Mlcochova P, Watters SA, et al. Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo. Clin Infect Dis. 2015; 61 (1): 120-128.
13. Walker-Sperling VE, Cohen VJ, Tarwater PM, et al. Reactivation kinetics of HIV-1 and susceptibility of reactivated latently infected CD4+ T cells to HIV-1-specific CD8+ T cells. J Virol. 2015;89(18):9631-9638.
14. Shin H, Iwasaki A. Tissue-resident memory T cells. Immunol Rev. 2013; 255 (1): 165-181.
15. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012; 491 (7424): 463-467.
16. Korber B, Gaschen B, Yusim K, et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001; 58: 19-42.
17. Freed EO. HIV-1 assembly, release and maturation. Nat Reviews Microbiol. 2015; 13 (8): 484-496.
18. Williamson C, Morris L, Maughan MF, et al. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses. 2003; 19 (2): 133-144.
19. van Harmelen JH, Shephard E, Thomas R, et al. Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine. 2003; 21 (27-30): 4380-4389.
20. Carr JK. Viral diversity as a challenge to HIV-1 vaccine development. Curr Opin HIV AIDS. 2006; 1 (4): 294-300.
21. Fischer W, Perkins S, Theiler J, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med. 2007; 13 (1): 100-106.
22. Borthwick NJ, Rosario M, Schiffner T, et al. Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques. Immun Inflamm Dis. 2015; 3 (2): 82-93.
23. Stephenson KE, SanMiguel A, Simmons NL, et al. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol. 2012; 86 (21): 11434-11440.
24. Borthwick N, Ahmed T, Ondondo B, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Therapy: Journal Am Soc Gene Ther. 2014; 22 (2): 464-475.
25. Ndhlovu ZM, Piechocka-Trocha A, Vine S, et al. Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J Immunology. 2011; 186 (12): 6914-6924.
26. Santra S, Liao HX, Zhang R, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med. 2010; 16 (3): 324-328.
27. Santra S, Muldoon M, Watson S, et al. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology. 2012; 428 (2): 121-127.
28. Poropatich K, Sullivan DJ Jr. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J Gen Virol. 2011; 92 (Pt 2): 247-268.
29. Autran B, Descours B, Avettand-Fenoel V, et al. Elite controllers as a model of functional cure. Curr Opin HIV AIDS. 2011; 6 (3): 181-187.
30. Rolland M, Heckerman D, Deng W, et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. Plos One. 2008; 3 (1): e1424.
31. Prendergast A, Goodliffe H, Clapson M, et al. Gag-specific CD4+ T-cell responses are associated with virological control of paediatric HIV-1 infection. Aids. 2011; 25 (10): 1329-1331.
32. Leligdowicz A, Yindom LM, Onyango C, et al. Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J Clin Invest. 2007; 117 (10): 3067-3074.
33. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008; 197 (4): 563-571.
34. De Silva TI, Peng Y, Leligdowicz A, et al. Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection. Blood. 2013; 121 (21): 4330-4339.
35. Kunwar P, Hawkins N, Dinges WL, et al. Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design. Plos One. 2013; 8 (5): e64405.
36. Buckheit RW 3rd, Siliciano RF, Blankson JN. Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells. Retrovirology. 2013; 10: 68.
37. Ranasinghe S, Flanders M, Cutler S, et al. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol. 2012; 86 (1): 277-283.
38. Porichis F, Kaufmann DE. HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS. 2011; 6 (3): 174-180.
39. Arrode G, Finke JS, Zebroski H, et al. CD8+ T cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses. Eur J Immunol. 2005; 35 (1): 159-170.
40. Buckheit RW 3rd, Salgado M, Silciano RF, et al. Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors. J Virol. 2012; 86 (24): 13679-13688.
41. Kaul R, Rowland-Jones SL, Kimani J, et al. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett. 2001; 79 (1-2): 3-13.
42. Lohman-Payne B, Slyker J, Rowland-Jones SL. Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization. Clin Perinatol. 2010; 37 (4): 787-805, ix.
43. John-Stewart GC, Mbori-Ngacha D, Payne BL, et al. HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. J Infect Dis. 2009; 199 (6): 889-898.
44. Ruiz-Riol M, Llano A, Ibarrondo J, et al. Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. J Infect Dis. 2015; 211 (6): 936-946.
45. Pala P, Serwanga J, Watera C, et al. Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners. J Virol. 2013; 87 (16): 9053-9063.
46. Bradac J, Dieffenbach CW. HIV vaccine development: lessons from the past, informing the future. IDrugs. 2009; 12 (7): 435-439.
47. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372 (9653): 1894-1905.
48. Dommaraju K, Kijak G, Carlson JM, et al. CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants. Plos One. 2014; 9 (10): e111334.
49. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361 (23): 2209-2220.
50. Janes H, Friedrich DP, Krambrink A, et al. Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. J Infect Dis. 2013; 208 (8): 1231-1239.
51. Penaloza-MacMaster P, Provine NM, Ra J, et al. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol. 2013; 87 (3): 1373-1384.
52. Evans DT, Silvestri G. Nonhuman primate models in AIDS research. Curr Opin HIV AIDS. 2013; 8 (4): 255-261.
53. Sui Y, Gordon S, Franchini G, et al. Nonhuman primate models for HIV/AIDS vaccine development. Curr Protoc Immunol. 2013; 102:12.14.1-12.14.30.
54. Casimiro DR, Wang F, Schleif WA, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol. 2005; 79 (24): 15547-15555.
55. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415 (6869): 331-335.
56. Reynolds MR, Weiler AM, Piaskowski SM, et al. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine. 2012; 30 (30): 4465-4475.
57. Friedrich TC, Watkins DI. Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus. Curr Opin HIV AIDS. 2008; 3 (3): 393-398.
58. Casimiro DR, Cox K, Tang A, et al. Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge. J Virol. 2010; 84 (6): 2996-3003.
59. Schell JB, Bahl K, Folta-Stogniew E, et al. Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus. Virology. 2015; 476: 405-412.
60. Genesca M, McChesney MB, Miller CJ. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med. 2009; 265 (1): 67-77.
61. Vaccari M, Mattapallil J, Song K, et al. Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J Virol. 2008; 82 (19): 9629-9638.
62. Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011; 473 (7348): 523-527.
63. Hansen SG, Piatak M Jr., Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature. 2013; 502 (7469): 100-104.
64. Chapman R, Chege G, Shephard E, et al. Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res. 2010; 8 (4): 282-298.
65. Ami Y, Izumi Y, Matsuo K, et al. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol. 2005; 79 (20): 12871-12879.
66. Sixsmith JD, Panas MW, Lee S, et al. Recombinant Mycobacterium bovis bacillus Calmette-Guerin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques. Clin Vaccine Immunol. 2014; 21 (10): 1385-1395.
67. Lu W, Chen S, Lai C, et al. Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep. 2012; 2 (6): 1736-1746.
68. Andrieu JM, Chen S, Lai C, et al. Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model. Front Immunol. 2014; 5: 297.
69. Ondondo BO. The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol. 2014; 5: 439.
70. McShane H. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther. 2002; 4 (1): 23-27.
71. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009; 21 (3): 346-351.
72. Masopust D, Ha SJ, Vezys V, et al. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunology. 2006; 177 (2): 831-839.
73. Masopust D. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location. J Intern Med. 2009; 265 (1): 125-137.
74. Schenkel JM, Fraser KA, Vezys V, et al. Sensing and alarm function of resident memory CD8(+) T cells. Nat Immunol. 2013; 14 (5): 509-513.
75. Keefer MC, Frey SE, Elizaga M, et al. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine. 2011; 29 (10): 1948-1958.
76. Burgers WA, Ginbot Z, Shen YJ, et al. The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques. J Gen Virol. 2014; 95 (Pt 10): 2267-2272.
77. Burgers WA, Chege GK, Muller TL, et al. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol. 2009; 90 (Pt 2): 468-480.
78. Garcia-Arriaza J, Perdiguero B, Heeney J, et al. Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime/boost combination with Env protein in non-human primates. J Virol. 2015;89(16):8525-8539.
79. Offerman K, Deffur A, Carulei O, et al. Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse model. BMC Genomics. 2015; 16: 510.
80. Yates NL, Liao HX, Fong Y, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014; 6 (228): 228ra239.
81. van Harmelen J, Williamson C, Kim B, et al. Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses. 2001; 17 (16): 1527-1531.
82. Abrahams MR, Treurnicht FK, Ngandu NK, et al. Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression. Aids. 2013; 27 (4): 507-518.
83. Williamson C, Engelbrecht S, Lambrick M, et al. HIV-1 subtypes in different risk groups in South Africa. Lancet. 1995; 346 (8977): 782.
84. Williamson AL, Rybiki E, Shephard E, et al. South African HIV-1 vaccine candidates-the journey from the bench to clinical trials. S Afr Med J. 2012; 102 (6): 452-455.
85. Harari A, Bart PA, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008; 205 (1): 63-77.
86. Burgers WA, Shephard E, Monroe JE, et al. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses. 2008; 24 (2): 195-206.
87. Adams SE, Dawson KM, Gull K, et al. The expression of hybrid HIV:Ty virus-like particles in yeast. Nature. 1987; 329 (6134): 68-70.
88. Mills KH, Kitchin PA, Mahon BP, et al. HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1. J Immunology. 1990; 144 (5): 1677-1683.
89. Harris SJ, Gearing AJ, Layton GT, et al. Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3:Ty virus-like particles. Immunology. 1992; 77 (3): 315-321.
90. Layton GT, Harris SJ, Gearing AJ, et al. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J Immunology. 1993; 151 (2): 1097-1107.
91. Martin SJ, Vyakarnam A, Cheingsong-Popov R, et al. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. Aids. 1993; 7 (10): 1315-1323.
92. Dale CJ, Liu XS, De Rose R, et al. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology. 2002; 301 (1): 176-187.
93. Gheysen D, Jacobs E, de Foresta F, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell. 1989; 59 (1): 103-112.
94. Jacobs E, Gheysen D, Thines D, et al. The HIV-1 Gag precursor Pr55gag synthesized in yeast is myristoylated and targeted to the plasma membrane. Gene. 1989; 79 (1): 71-81.
95. Mergener K, Facke M, Welker R, et al. Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology. 1992; 186 (1): 25-39.
96. Luo L, Li Y, Dales S, et al. Mapping of functional domains for HIV-2 gag assembly into virus-like particles. Virology. 1994; 205 (2): 496-502.
97. Wagner R, Deml L, Schirmbeck R, et al. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development. Behring Inst Mitt. 1994; 95: 23-34.
98. Wagner R, Deml L, Schirmbeck R, et al. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology. 1996; 220 (1): 128-140.
99. Halsey RJ, Tanzer FL, Meyers A, et al. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Virus Res. 2008; 133 (2): 259-268.
100. Pillay S, Meyers A, Williamson AL, et al. Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system. Biotechnol Prog. 2009; 25 (4): 1153-1160.
101. Pillay S, Shephard EG, Meyers AE, et al. HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice. J Immune Based Ther Vaccines. 2010; 8: 7.
102. Buonaguro L, Buonaguro FM, Tornesello ML, et al. High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res. 2001; 49 (1): 35-47.
103. Osterrieder N, Wagner R, Brandmuller C, et al. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology. 1995; 208 (2): 500-510.
104. Yamshchikov GV, Ritter GD, Vey M, et al. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology. 1995; 214 (1): 50-58.
105. Paliard X, Liu Y, Wagner R, et al. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses. 2000; 16 (3): 273-282.
106. Montefiori DC, Safrit JT, Lydy SL, et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol. 2001; 75 (13): 5879-5890.
107. Deml L, Speth C, Dierich MP, et al. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol. 2005; 42 (2): 259-277.
108. Jaffray A, Shephard E, van Harmelen J, et al. Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J Gen Virol. 2004; 85 (Pt 2): 409-413.
109. Chege GK, Shephard EG, Meyers A, et al. HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J Gen Virol. 2008; 89 (Pt 9): 2214-2227.
110. Chege GK, Thomas R, Shephard EG, et al. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine. 2009; 27 (35): 4857-4866.
111. Chege GK, Burgers WA, Stutz H, et al. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. J Virol. 2013; 87 (9): 5151-5160.
112. Singh V, Chege G, Shephard E, et al. Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen. Retrovirology. 2012; 9 (Suppl. 2): 1.
113. Zanotto C, Elli V, Basavecchia V, et al. Evaluation in rabbits of different anti-SHIV vaccine strategies based on DNA/fowlpox priming and virus-like particle boosting. FEMS Immunol Med Microbiol. 2003; 35 (1): 59-65.
114. Buonaguro L, Tornesello ML, Tagliamonte M, et al. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol. 2006; 80 (18): 9134-9143.
115. McBurney SP, Ross TM. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine. 2009; 27 (32): 4337-4349.
116. Lynch AG, Tanzer F, Fraser MJ, et al. Use of the piggyBac transposon to create HIV-1 gag transgenic insect cell lines for continuous VLP production. BMC Biotechnol. 2010; 10: 30.
117. Yang L, Song Y, Li X, et al. HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component. J Virol. 2012; 86 (14): 7662-7676.
118. Valley-Omar Z, Meyers AE, Shephard EG, et al. Abrogation of contaminating RNA activity in HIV-1 Gag VLPs. Virol J. 2011; 8: 462.
119. Lynch A, Meyers AE, Williamson AL, et al. Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media. Virol J. 2012; 9: 210.
120. Scotti N, Rybicki EP. Virus-like particles produced in plants as potential vaccines. Expert Rev Vaccines. 2013; 12 (2): 211-224.
121. Rybicki EP. Plant-based vaccines against viruses. Virol J. 2014; 11: 205.
122. Scotti N, Alagna F, Ferraiolo E, et al. High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta. 2009; 229 (5): 1109-1122.
123. Kessans SA, Linhart MD, Matoba N, et al. Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana. Plant Biotechnol J. 2013; 11 (6): 681-690.
124. Smith JM, Amara RR, Campbell D, et al. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses. 2004; 20 (12): 1335-1347.
125. Ellenberger D, Wyatt L, Li B, et al. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02-AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology. 2005; 340 (1): 21-32.
126. Hellerstein M, Xu Y, Marino T, et al. Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine. Hum Vaccin Immunother. 2012; 8 (11): 1654-1658.
127. Kwa S, Lai L, Gangadhara S, et al. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. J Virol. 2014; 88 (17): 9579-9589.